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A2 Abstracts
tions based on a single treatment feature such as cost, or select
the current-treatment alternative in all questions. We used probit
models to identify the chracteristics of subjects who are more
likely to reject scenarios and controlled for scenario rejection in
estimating preference models. RESULTS: 463 respondents com-
pleted the survey. 12.4% of respondents did not answer the
trade-off questions, 40.6% dominated on price, and 51.3%
chose their current treatment in all trade-off questions. Respon-
dents were less likely to reject scenarios if they had higher
incomes (p < 0.000), more education (p < 0.000), were recently
diagnosed with RA (p = 0.006), and if the cost of their current
treatment was high (p < 0.000). Respondents who currently use
an oral medication are less likely and respondents who currently
use an injected or infused treatment are more likely to always
pick current treatment. Controlling for price-dominant subjects
increases willingness to pay for the “chance that the medicine
works well 100% of the time” from $217 ($166–$268) to $471
($396–$545) per month. CONCLUSION: Scenario rejection is
a form of selection bias. Rejectors provide no trade-off infor-
mation for estimating treatment preferences. Rejection is corre-
lated with several observable variables, which makes it possible
to control for potential bias in preference estimation. Control-
ling for price-dominant subjects can have a large impact on WTP
estimates.
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OBJECTIVES: To identify the most reliable approach for 
measuring dose escalation by comparing results from different
methods that may affect clinical and drug utilization decisions.
METHODS: Five methods of quantifying dose escalation were
explored which compared: 1) weekly dose of last to ﬁrst pre-
scription; 2) average weekly dose of all prescriptions to standard
dose; 3) weekly dose of subsequent prescriptions to ﬁrst pre-
scription and 3a) deﬁning dose escalation as °Y´2 instances of
dose increase; 3b) deﬁning dose escalation by proportional dose
increase (15%, 30%, or 50%); and 3c) calculating dose escala-
tion as percent of patient-weeks. The example is based on claims
data from 2002 to 2004, using RA patients newly initiated anti-
TNFα (Enbrel or Humira) treatment with one year follow-up.
Separate analyses were conducted for patients started on stan-
dard and high doses. RESULTS: For those who started on stan-
dard dose, dose escalation by method 1 and 2 was 6.2% and
8.4% for Enbrel patients (n = 1339) and, 13.7% and 26.6% for
Humira patients (n = 417). Dose escalation by method 3a was
8.1% for Enbrel and 18.9% for Humira. Dose escalation by
method 3b (with threshold of 15%, 30%, and 50%) ranged from
5.6% to 7.7% for Enbrel and 16.1% to 18.5% for Humira,
respectively. Percent patient-time approach of 3c provides weekly
incidences of dose escalation and exhibits a divergent pattern of
dose escalation between the treatment groups over time, which
diverges at about the 12th week of treatment. Dose escalation
was uncommon in patients started with high dose. CONCLU-
SION: Estimate of dose escalation is method dependent. Simple
approaches such as comparing last and ﬁrst prescription were
unable to capture the full extent of dose escalation. Use of mul-
tiple methods, such as method 3 and method 2 are recommended
as the latter will also address dosing for patients initiated with
high doses.
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OBJECTIVES: Evaluate a patient Formulary Notiﬁcation
Program (FNP) designed to encourage use of lower cost, clini-
cally equivalent generic alternatives among non-formulary 
atorvastatin users. METHODS: This was a cross-sectional, case-
control study conducted in a commercially insured population,
targeting current atorvastatin users (date of last ﬁll + days supply
within 30 days of targeting). The case group received one of two
letter-based Patient Communications (PCs) depending on
channel of most current prescription ﬁll (target prescription).
The PCs informed patients of lower cost, clinically equivalent
generic alternatives. Patients in retail pharmacies (n = 27,449)
received information on copayment savings from generic use in
retail. Patients in Home Delivery (HD) (n = 25,274) received
information on savings from ﬁlling generic alternatives in HD.
The PCs were mailed in July 2006 soon after availability of
generic simvastatin. The control group consisted of current ator-
vastatin users (at time of case group targeting) who were not
enrolled in a client that implemented the FNP. Control group
members were matched to case group based on distribution
channel [retail (n = 3186)/HD (n = 1012)] of target prescription.
Prescription claims were examined through October 2006 for the
outcome of switching to generic statin. Bivariate and logistic
regression analyses were used to assess research objective.
RESULTS: In retail, 11.9% of cases switched to generic statin
compared to 4.8% in control group (p < 0.001). In HD, 20.6%
of cases switched to generic statin compared to 8.1% in control
group (p < 0.001). Controlling for demographic and plan design,
patients who received PCs in retail had 64% greater odds
(95%CI: 1.48–1.81) of ﬁlling generics relative to controls.
Patients receiving PCs in HD had 81% greater odds (95%CI:
1.60–2.05) of ﬁlling generics in HD compared to respective con-
trols. CONCLUSION: Informing patients of copayment savings
from generic alternatives soon after patent expiration of a
popular branded statin, is an effective strategy to encourage
greater generic statin use.
CV2
MEDICATION REFILL PERSISTENCE: DOES PRESCRIPTION
COST-SHARING MATTER?
Zhang D1, Carlson AM2, Gleason PP3, Schondelmeyer SW4,
Schommer JC4, Dowd BE4, Heaton AH5
1IMS Health, Blue Bell, PA, USA, 2Data Intelligence Consultants LLC,
Eden Prairie, MN, USA, 3Prime Therapeutics LLC, Eagan, MN, USA,
4University of Minnesota, Minneapolis, MN, USA, 5BlueCross
BlueShield of Minnesota, Eagan, MN, USA
OBJECTIVES: To investigate and to quantify the inﬂuence 
prescription cost-sharing has on medication reﬁll persistence 
by using two antihypertensive therapeutic classes: ACEs
(angiotensin converting enzyme inhibitors) and ARBs
(angiotensin II receptor blockers). METHODS: This is an obser-
vational cohort study utilizing a commercial insurer’s integrated
medical and pharmacy claims database supplemented with
public ﬁles. Members were new users of ACE and ARB single
agents between January 1 and June 30, 2004. Medication reﬁll
persistence was measured three ways: total number of days
without medication; proportion of days covered (PDC) with a
cutoff point of 80%; and number of days to the ﬁrst gap of more
